Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Lung Cancer

 

ABRAXANE® (Nab-Paclitaxel) for Advanced NSCLC (7755)
A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors

Investigator: Christina Baik;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01620190

Radiation Therapy + Cisplatin & Etoposide for Inoperable NSCLC (7506)
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer

Investigator: Shilpen Patel, MD;   Conditions: Lung Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01411098

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy (8180)
Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01982123

Early Diagnosis of Pulmonary Nodules (2658)
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier

Investigator: David Madtes, MD;   Conditions: Precancerous Conditions;    Status: Recruiting;   Study ID: NCT01752114

Safety and Tolerability of Nivolumab (BMS-936558) for Non-small Cell Lung Cancer (UW11037)
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab maintenance, Erlotinib, Ipilimumab or monotherapy in First line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01454102

Proton Beam Radiation Therapy for Recurrent Thoracic Cancer (9148)
Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02204761

BRAF Kinase Inhibitor GSK2118436 for Advanced NSCLC and BRAF Mutations (UW12020)
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Investigator: Renato G. Martins, MD;   Conditions: Advanced Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01336634

Alisertib (MLN8237) in Combination With Paclitaxel for Small Cell Lung Cancer (UW14002)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).

Investigator: Christina S. Baik, MD;   Conditions: Small Cell Lung Cancer;    Status: Pending;   Study ID: NCT02038647

LY2875358 + Erlotinib for Non-Small-Cell Lung Cancer (I4C-MC-JTBC)
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib

Investigator: Renato G. Martins, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01900652

MEDI4736 (Anti PD-L1) w/ Gefitinib for Non-Small Cell Lung Cancer (UW14005)
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)

Investigator: Laura Chow, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02088112

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01727076

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

CO-1686 for Non-Small Cell Lung Cancer (UW14031)
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Investigator: Christina S. Baik, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Pending;   Study ID: NCT01526928

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer (UW14019)
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent

Investigator: Laura Chow, MD;   Conditions: Non-Small-Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02119650

Oral MGCD265 for Advanced Cancer (UW13036)
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Investigator: Keith Eaton, MD;   Conditions: Advanced Cancer;    Status: Recruiting;   Study ID: NCT00697632

CO-1686 vs. Erlotinib for Non-Small Cell Lung Cancer (UW14055)
TIGER 1: A Randomized, Open-Label, Phase 2 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced NSCLC

Investigator: ;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02186301